6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00809302 (ClinicalTrials.gov)	December 2008	15/12/2008	Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1, 3, and 6 mg Twice Daily) in Patients With Early Parkinson Disease (APLIED)	Early Parkinson Disease	Drug: aplindore MR tablets or Placebo	Neurogen Corporation	NULL	Terminated	30 Years	N/A	Both	9	Phase 2	United States
2	NCT00623324 (ClinicalTrials.gov)	January 2008	14/2/2008	The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease	A Phase II, Dose Ranging, Randomized, Double Blind, Placebo-controlled, Multi-center, Pilot Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of Aplindore in Patients With Early Stage Parkinson's Disease	Early Stage Parkinson's Disease	Drug: Aplindore;Drug: Placebo	Ligand Pharmaceuticals	NULL	Completed	30 Years	N/A	Both	40	Phase 2	United States